Crescendo Biologics of the UK has raised £17.5m ($28m) in a series A financing led by Imperial Innovations and including new investor Astellas Venture Management (AVM). The UK biotech says the cash will fund its lead program, which is in topical dermatology, through to clinical proof of concept. Founding seed investor Sofinnova Partners also contributed significantly to the round.
Crescendo Biologics of the UK has raised £17.5m ($28m) in a series A financing led by Imperial Innovations and including new investor Astellas Venture Management (AVM). The UK biotech says the cash will fund its lead program, which is in topical dermatology, through to clinical proof of concept. Founding seed investor Sofinnova Partners also contributed significantly to the round.
Crescendo's in-house development program, focused on topical inflammation
Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
